<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03959839</url>
  </required_header>
  <id_info>
    <org_study_id>DSETAMIS-2018</org_study_id>
    <nct_id>NCT03959839</nct_id>
  </id_info>
  <brief_title>Endoscopic Submucosal Dissection vs Local Laparoscopic Surgical Resection (TAMIS/TEO) in Early Rectal Neoplasias</brief_title>
  <acronym>DSETAMIS2018</acronym>
  <official_title>Endoscopic Submucosal Dissection Versus Local Laparoscopic Surgical Resection (Transanal Minimally Invasive Surgery [TAMIS] / Transanal Endoscopic Operation [TEO]) In Early Rectal Neoplasias. Multicentric and Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Alberto Herreros de Tejada Echanojáuregui</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Society of Digestive Endoscopy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Puerta de Hierro University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter non-inferiority randomized clinical trial to compare Endoscopic treatment (ESD)&#xD;
      and Minimally Invasive Laparoscopic Local Surgical Treatment (TAMIS or TEO) for early rectal&#xD;
      neoplastic lesions (adenoma &amp; T1CRC) Primary aim: To compare the long-term local recurrence&#xD;
      rate (12 months after the procedure)&#xD;
&#xD;
      Secondary aims:&#xD;
&#xD;
      Compare en-bloq resection rate, R0 resection, time per procedure, short-term recurrence rate,&#xD;
      safety (rate of complications), morbidity and cost-effectiveness analyses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter non-inferiority randomized clinical trial is proposed to compare two types of&#xD;
      treatment for early rectal neoplastic lesions. Study arms:&#xD;
&#xD;
        1. Endoscopic treatment: Endoscopic Submucosal Dissection (ESD)&#xD;
&#xD;
        2. Minimally invasive laparoscopic local surgical treatment: Transanal Minimally Invasive&#xD;
           Surgery (TAMIS) or Transanal Endoscopic Operation (TEO).&#xD;
&#xD;
      Aims:&#xD;
&#xD;
      Primary aim: To compare the long-term local recurrence rate (12 months after the procedure)&#xD;
      of rectal lesions after ESD vs Surgical treatment (TAMIS/TEO).&#xD;
&#xD;
      Secondary aims: Both arms of the study are compared according to other efficacy-related&#xD;
      variables (en-bloq resection rate, R0 resection, time per procedure, short-term recurrence&#xD;
      rate [6 months]), safety (rate of complications), morbidity (comparing different specific&#xD;
      indexes: Wexner index, EQ-5L-5D, etc) and cost-effectiveness analyses (QALY).&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        -  Patients older than 18 y/o&#xD;
&#xD;
        -  Non-pedunculated rectal lesions (sessile 0-Is or flat 0-II) greater than 20 mm in&#xD;
           diameter.&#xD;
&#xD;
        -  The edges of the lesion should be more than 3 cm from the external anal margin and up to&#xD;
           14 cm from it.&#xD;
&#xD;
        -  Circumferential involvement &lt;50%&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        -  Patients who refuse to participate.&#xD;
&#xD;
        -  Diagnosis of inflammatory bowel disease with rectal involvement.&#xD;
&#xD;
        -  Pregnant.&#xD;
&#xD;
        -  Anorectal fibrosis due to previous anorectal surgery.&#xD;
&#xD;
        -  Lateral Spreading Lesions (LST classification) Granular Homogeneous type&#xD;
&#xD;
        -  Lesions greater than 50 mm when there is suspicion of advanced histology (Kudo Vi&#xD;
           superficial pattern).&#xD;
&#xD;
        -  Rectal lesions of any size with high suspicion of deep submucosal invasion or&#xD;
           locoregional lymph node involvement, either in the diagnostic colonoscopy (Kudo Vn crypt&#xD;
           pattern, NICE 3 pattern, Sano IIIB pattern) or by complementary imaging tests (rectal&#xD;
           EUS/Pelvic MRI)&#xD;
&#xD;
        -  Existence of synchronous colorectal lesions that require other surgical treatment in any&#xD;
           case.&#xD;
&#xD;
      N-size estimation:&#xD;
&#xD;
      Assuming a global rate of long-term local recurrence in rectal lesions treated by TAMIS/TEO&#xD;
      or ESD of 2.5% (using the data available in the medical literature), considering a&#xD;
      non-inferiority limit of 10%, power of 80% (Beta error 0.2, alpha error 0.05) and assuming a&#xD;
      loss of patients during the follow-up around 10%, 34 patients per group are required.&#xD;
&#xD;
      Follow-up and Information collect:&#xD;
&#xD;
      The follow-up will be of 1 year from the date of the intervention and the visits in which the&#xD;
      information to be analyzed will be collected are adjusted to the usual clinical practice.&#xD;
&#xD;
      The data would be registered using the on-line database system for medical research RedCap.&#xD;
&#xD;
      Other information:&#xD;
&#xD;
      The entire protocol of this study has been approved by de Ethical Committee on Clinical&#xD;
      Research of the Puerta de Hierro University Hospital.&#xD;
&#xD;
      The study counts with a Civil Responsibility Insurance policy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>local recurrence rate</measure>
    <time_frame>12 months</time_frame>
    <description>presence of remaining neoplastic tissue in resection site</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>En-bloq resection rate</measure>
    <time_frame>1 hour</time_frame>
    <description>Single piece of resection specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>1 hour</time_frame>
    <description>Free margin of neoplastic tissue both laterally and deep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time per procedure</measure>
    <time_frame>1 hour</time_frame>
    <description>The length of the procedure expressed in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>1 hour</time_frame>
    <description>Days of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early complications rate</measure>
    <time_frame>1 hour</time_frame>
    <description>Registration of any deviations on the normal postoperative period in the first 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed complications rate</measure>
    <time_frame>1 hour</time_frame>
    <description>Registration of any deviations on the normal postoperative period after the first 24 hours and up to 30 days after the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in patients' quality of life using validated scores (both, specific and non-specific)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness analyses (QALY)</measure>
    <time_frame>12 months</time_frame>
    <description>Cost-effectiveness analyses usin QALYs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term local recurrence rate</measure>
    <time_frame>6 months</time_frame>
    <description>Presence of remaining neoplastic tissue in resection site</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Rectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Endoscopic Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rectal Endoscopic Submucosal Dissection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minimally Invasive Laparoscopic Local Surgical Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transanal Minimally Invasive Surgery (TAMIS) or Transanal Endoscopic Operation (TEO)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ESD</intervention_name>
    <description>Rectal Endoscopic Submucosal Dissection</description>
    <arm_group_label>Endoscopic Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAMIS</intervention_name>
    <description>Transanal Minimally Invasive Surgery</description>
    <arm_group_label>Minimally Invasive Laparoscopic Local Surgical Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TEO</intervention_name>
    <description>Transanal Endoscopic Operation</description>
    <arm_group_label>Minimally Invasive Laparoscopic Local Surgical Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 18 y/o&#xD;
&#xD;
          -  Non-pedunculated rectal lesions (sessile 0-Is or flat 0-II) greater than 20 mm in&#xD;
             diameter.&#xD;
&#xD;
          -  The edges of the lesion should be more than 3 cm from the external anal margin and up&#xD;
             to 14 cm from it.&#xD;
&#xD;
          -  Circumferential involvement &lt;50%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who refuse to participate.&#xD;
&#xD;
          -  Diagnosis of inflammatory bowel disease with rectal involvement.&#xD;
&#xD;
          -  Pregnant.&#xD;
&#xD;
          -  Anorectal fibrosis due to previous anorectal surgery.&#xD;
&#xD;
          -  Lateral Spreading Lesions (LST classification) Granular Homogeneous type&#xD;
&#xD;
          -  Lesions greater than 50 mm when there is suspicion of advanced histology (Kudo Vi&#xD;
             superficial pattern).&#xD;
&#xD;
          -  Rectal lesions of any size with high suspicion of deep submucosal invasion or&#xD;
             locoregional lymph node involvement, either in the diagnostic colonoscopy (Kudo Vn pit&#xD;
             pattern, NICE 3 pattern, Sano IIIB pattern) or by complementary imaging tests (rectal&#xD;
             EUS/Pelvic MRI)&#xD;
&#xD;
          -  Existence of synchronous colorectal lesions that require other surgical treatment in&#xD;
             any case.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Albéniz, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Complejo Hospitalario de Navarra</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diego de Frutos, MD</last_name>
    <phone>+34600826265</phone>
    <email>diegodefrutos@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alberto Herreros de Tejada, MD, PhD</last_name>
    <email>alberto.herreros@salud.madrid.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Álvaro Terán</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Montepríncipe</name>
      <address>
        <city>Boadilla Del Monte</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felipe Ramos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego de Frutos, MD</last_name>
      <phone>600826265</phone>
      <email>diegodefrutos@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital QuironSalud Málaga</name>
      <address>
        <city>Málaga</city>
        <state>Malaga</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pedro Rosón, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eduardo Albeniz, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Joan Despí Moisès Broggi</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Barquero</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oscar Nogales</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Carlos Marín</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Puerta de Hierro University Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Alberto Herreros de Tejada Echanojáuregui</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Early Rectal Neoplasms</keyword>
  <keyword>ESD</keyword>
  <keyword>TAMIS</keyword>
  <keyword>TEO</keyword>
  <keyword>Recurrence</keyword>
  <keyword>R0</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

